Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 1/20 | 0.50 |
| ▸ | CA9 | Q16790 | 1/20 | 0.50 |
| ▸ | CDK5 | Q00535 | 2/20 | 0.44 |
| ▸ | DYRK1A | Q13627 | 2/20 | 0.44 |
| ▸ | CLK4 | Q9HAZ1 | 2/20 | 0.44 |
| ▸ | PIM1 | P11309 | 1/20 | 0.44 |
| ▸ | CSNK1A1 | P48729 | 1/20 | 0.44 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.44 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.44 |
| ▸ | DYRK1B | Q9Y463 | 1/20 | 0.44 |
| ▸ | TDP2 | O95551 | 1/20 | 0.43 |
| ▸ | NSD2 | O96028 | 1/20 | 0.43 |
| ▸ | ABL1 | P00519 | 1/20 | 0.43 |
| ▸ | PLCG1 | P19174 | 1/20 | 0.43 |
| ▸ | CES1 | P23141 | 1/20 | 0.43 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.43 |
| ▸ | RIN1 | Q13671 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | THRB | P10828 | 1/20 | 0.43 |
| ▸ | BLM | P54132 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4670599 | 0.82 | TDP2 (0.39) | CA12CA9CDK5DYRK1ACLK4 | |
| SCHEMBL30975576 | 0.80 | TDP2 (0.41) | CA12CA9CDK5DYRK1ACLK4 | |
| SCHEMBL299004 | 0.80 | PARP1 (0.53) | PARP1CYP1A2PDPK1PARP10PARP11 | |
| SCHEMBL2715285 | 0.77 | PARP1 (0.46) | TDP2NSD2ABL1PLCG1CES1 | |
| SCHEMBL13629294 | 0.76 | GAA (0.46) | CDK5TDP2NSD2ABL1PLCG1 | |
| SCHEMBL299769 | 0.75 | TDP2 (0.52) | CDK5TDP2NSD2ABL1PLCG1 | |
| SCHEMBL3273699 | 0.75 | TDP1 (0.35) | TDP2NSD2ABL1PLCG1CES1 | |
| SCHEMBL9407864 | 0.73 | JAK2 (0.45) | CDK5TDP2NSD2ABL1PLCG1 | |
| SCHEMBL8484211 | 0.72 | CYP1A2 (0.56) | CDK5LRRK2DYRK1BGAACYP1A2 | |
| SCHEMBL29110040 | 0.71 | TSHR (0.46) | CDK5TDP2NSD2ABL1PLCG1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 163 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3365334-B1 | BENZOLACTAM COMPOUNDS AS PROTEIN KINASE INHIBITORS | OTSUKA PHARMA CO LTD (JP) | 2024-07-17 | — | — | EP | claimed |
| WO-2024086569-A1 | POSITIVE ALLOSTERIC MODULATORS OF THE MUSCARINIC ACETYLCHOLINE RECEPTOR M1 | VANDERBILT UNIVERSITY (US) | 2024-04-25 | — | — | WO | claimed |
| US-11939321-B2 | Benzolactam compounds as protein kinase inhibitors | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2024-03-26 | — | — | US | claimed |
| WO-2022253252-A1 | HETEROCYCLIC COMPOUNDS USEFUL AS HPK1 INHIBITORS | SILEXON BIOTECH CO., LTD. (CN) | 2022-12-08 | — | — | WO | claimed |
| EP-3644990-B1 | 5-(PYRIDIN-3-YL)OXAZOLE ALLOSTERIC MODULATORS OF THE M4 MUSCARINIC ACETYLCHOLINE RECEPTOR | MERCK SHARP & DOHME LLC (US) | 2022-11-30 | — | — | EP | claimed |
| CN-108617166-B | Protein kinase inhibitor benzolactam compounds | 大冢制药株式会社 | 2022-05-17 | — | — | CN | claimed |
| EP-3713940-B1 | SUBSTITUTED AZACYCLES AS MUSCARINIC M1 RECEPTOR POSITIVE ALLOSTERIC MODULATORS | SUVEN LIFE SCIENCES LTD (IN) | 2022-05-04 | — | — | EP | claimed |
| EP-3394061-A1 | 6,7-DIHYDRO-5H-PYRROLO[3,4-B]PYRIDIN-5-ONE ALLOSTERIC MODULATORS OF THE M4 MUSCARINIC ACETYLCHOLINE RECEPTOR | Merck Sharp & Dohme Corp. (US) | 2018-10-31 | — | — | EP | claimed |
| WO-2017112719-A1 | 6,7-DIHYDRO-5H-PYRROLO[3,4-B]PYRIDIN-5-ONE ALLOSTERIC MODULATORS OF THE M4 MUSCARINIC ACETYLCHOLINE RECEPTOR | MERCK SHARP & DOHME CORP. (US) | 2017-06-29 | — | — | WO | claimed |
| WO-2005011697-A2 | SULFONAMIDE DERIVATIVES WITH ACTIVITY ON PROTEIN KINASE A AND B | ASTEX THERAPEUTICS LIMITED (GB) | 2005-02-10 | — | — | WO | claimed |
| WO-2002018381-A1 | 6,7-DIHYDRO-PYRROLO[3,4-B]PYRIDIN-5-ONES WITH AN ANTICONVULSIVE ACTION AND METHODS FOR PRODUCING THE SAME | ARZNEIMITTELWERK DRESDEN GMBH (DE) | 2002-03-07 | — | — | WO | claimed |
| CN-122079878-A | Nitrogen-containing heterocyclic derivative inhibitor, preparation method and application thereof | — | 2026-05-26 | — | — | CN | disclosed |
| CN-122079879-A | Nitrogen-containing heterocyclic derivative inhibitor, preparation method and application thereof | — | 2026-05-26 | — | — | CN | disclosed |
| CN-122079880-A | Nitrogen-containing heterocyclic derivative inhibitor, preparation method and application thereof | — | 2026-05-26 | — | — | CN | disclosed |
| CN-120476110-B | Nitrogen-containing heterocyclic derivative inhibitor, preparation method and application thereof | SHANGHAI HANSOH BIOMEDICAL Co.,Ltd. (CN) | 2026-05-26 | — | — | CN | disclosed |
| WO-2005011697-A2 | SULFONAMIDE DERIVATIVES WITH ACTIVITY ON PROTEIN KINASE A AND B | ASTEX THERAPEUTICS LIMITED (GB) | 2005-02-10 | — | — | WO | disclosed |
| WO-2002018381-A1 | 6,7-DIHYDRO-PYRROLO[3,4-B]PYRIDIN-5-ONES WITH AN ANTICONVULSIVE ACTION AND METHODS FOR PRODUCING THE SAME | ARZNEIMITTELWERK DRESDEN GMBH (DE) | 2002-03-07 | — | — | WO | disclosed |
| WO-2002018381-A1 | 6,7-DIHYDRO-PYRROLO[3,4-B]PYRIDIN-5-ONES WITH AN ANTICONVULSIVE ACTION AND METHODS FOR PRODUCING THE SAME | ARZNEIMITTELWERK DRESDEN GMBH (DE) | 2002-03-07 | — | — | WO | disclosed |
| US-4379153-A | Benzenesulfonyl ureas, and pharmaceutical preparations | HOECHST AKTIENGESELLSCHAFT (DE) | 1983-04-05 | — | — | US | disclosed |
| EP-0029983-A1 | Benzenesulfonyl ureas, processes for their preparation and pharmaceutical compositions containing these compounds | HOECHST AKTIENGESELLSCHAFT (DE) | 1981-06-10 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11939321-B2 | Benzolactam compounds as protein kinase inhibitors | MAPK1, ALK, MAP3K1 | CA12 3975/4885CA9 2890/4885CDK5 159/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.